| # | Drug | Count |
|---|---|---|
| 0 | CISPLATIN | 24 |
| 1 | FLUOROURACIL | 22 |
| 2 | FLUOROURACIL CREAM, 0.5% | 22 |
| 3 | DOCETAXEL | 20 |
| 4 | DOCETAXEL ANHYDROUS | 20 |
| 5 | PEGFILGRASTIM | 14 |
| 6 | PEMBROLIZUMAB | 6 |
| 7 | CARBOPLATIN | 4 |
| 8 | PACLITAXEL | 4 |
| 9 | NIVOLUMAB | 3 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PEGFILGRASTIM | 14 | 0.0012 |
| 1 | SITAGLIPTIN PHOSPHATE | 2 | 0.0007 |
| 2 | CISPLATIN | 24 | 0.0003 |
| 3 | DOCETAXEL | 20 | 0.0003 |
| 4 | DOCETAXEL ANHYDROUS | 20 | 0.0003 |
| 5 | FLUOROURACIL CREAM, 0.5% | 22 | 0.0003 |
| 6 | FLUOROURACIL | 22 | 0.0003 |
| 7 | MIFEPRISTONE | 1 | 0.0002 |
| 8 | RAMUCIRUMAB | 1 | 0.0002 |
| 9 | TAZOBACTAM SODIUM AND PIPERACILLIN SODIUM | 1 | 0.0001 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Progestin Antagonist [EPC] | 1 | 0.0002 |
| 1 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 1 | 0.0002 |
| 2 | Microtubule Inhibitor [EPC] | 24 | 0.0001 |
| 3 | Platinum-based Drug [EPC] | 28 | 0.0001 |
| 4 | Leukocyte Growth Factor [EPC] | 14 | 0.0001 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 9 | 0.0001 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 23 | 0.0001 |
| 7 | CTLA-4-directed Blocking Antibody [EPC] | 2 | 0.0000 |
| 8 | Provitamin D2 Compound [EPC] | 1 | 0.0000 |
| 9 | Pyridone [EPC] | 1 | 0.0000 |